Menu
Search
|

Menu

Close
X

JiangSu Bicon Pharmaceutical Listed Co 002411.SZ (Shenzhen Stock Exchange)

24.98 CNY
-0.22 (-0.87%)
As of Feb 14
chart
Previous Close 25.20
Open 24.50
Volume 3,169,855
3m Avg Volume 1,897,781
Today’s High 24.98
Today’s Low 23.61
52 Week High 30.88
52 Week Low 20.71
Shares Outstanding (mil) 1,532.28
Market Capitalization (mil) 38,276.45
Forward P/E 43.25
Dividend (Yield %) 0.08 ( 0.32 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, CNY)
FY17
3,292
FY16
3,724
FY15
2,023
EPS (CNY)
FY17
0.405
FY16
0.673
FY15
0.624
*Note: Units in Millions of Renminbi
**Note: Units in Renminbi

KEY RATIOS

Price to Earnings (TTM)
vs sector
43.25
34.43
Price to Sales (TTM)
vs sector
8.79
8.57
Price to Book (MRQ)
vs sector
4.35
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
87.98
15.12
LT Debt to Equity (MRQ)
vs sector
79.39
11.85
Return on Investment (TTM)
vs sector
5.87
13.54
Return on Equity (TTM)
vs sector
10.50
14.80

EXECUTIVE LEADERSHIP

Xinji Zhou
, Since
Salary: --
Bonus: --
Xingfu Xiang
President, Vice Chairman of the Board, Since 2016
Salary: --
Bonus: --
Anjun Wu
Finance Director, Vice President, Director, Since 2017
Salary: --
Bonus: --
Bing Chen
Vice President, Secretary of the Board, Since 2016
Salary: --
Bonus: --
Jun Guo
Vice President, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

North Building of Financial Bure
No.18, Zhongwu South Road, Xinyi
XUZHOU   JNG   221400

Phone: +86516.88602411
Site:

JiangSu Bicon Pharmaceutical Listed Company, formerly Jiangsu Jiujiujiu Technology Co., LTD., is a China-based company, principally engaged in the research and development, manufacture and distribution of medical products, new energy materials and drug intermediates. The Company operates its businesses through three segments. The Pharmaceuticals segment provides circulatory system, digestive system, respiratory system, nervous system and ophthalmic products. The New Materials segment mainly consists of lithium hexafluorophosphate and high-strength and high modulus polyethylene fibers, among others. The Pharmaceutical Intermediates segment consists of 7-ADCA, benzaldehyde, 5.5-dimethylhydantion and trichloropyridine. The Company distributes its products in both domestic and overseas markets.

SPONSORED STORIES